Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study - Concepedia

Concepedia

Publication | Open Access

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

DOI Full Paper Access

154

Citations

38

References

2013

Year

Marc Gurwith, Michael Lock, Eve M. Taylor, Glenn Ishioka, Jeff Alexander, Tim Mayall, John Ervin, Richard N. Greenberg, Cynthia Strout, John J. Treanor,

The Lancet Infectious Diseases

Abstract

Wellcome Trust Foundation, PaxVax.

References

	Year	Citations

Page 1